Overview

* Tandem Q3 2025 sales rose to $249.3 mln, achieving record quarterly sales

* Adjusted net loss was slightly more than analysts' expectations

* Gross margin improved to 54% from 51% year-over-year

* Company reaffirmed full-year 2025 guidance, estimating $1.0 bln in sales

Outlook

* Company reaffirms 2025 sales guidance at approximately $1.0 bln

* Tandem expects 2025 U.S. sales of about $700 mln

* Company anticipates 2025 gross margin of 53% to 54%

Result Drivers

* RECORD SALES - Achieved record quarterly sales in both U.S. and international markets

* STRATEGIC INITIATIVES - Progressed multi-channel initiative including increased pharmacy benefit coverage and product clearances

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight -$21.20 -$21.10

Adjusted Miss* mln mln (16

Net Analysts

Income )

Q3 Net -$21.20

Income mln

Q3 Gross 54.00%

Margin

Q3 Miss -$22.90 -$22.40

Adjusted mln mln (15

Operatin Analysts

g income )

Q3 -$22.90

Operatin mln

g income

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 15 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Tandem Diabetes Care Inc ( TNDM ) is $15.50, about 5.4% above its November 5 closing price of $14.67

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)